

Original Article
Cardiovascular Disorders



Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling

Suk-Won Choi ,¹ Seongwoo Han ,¹ Wan Joo Shim ,² Dong-Ju Choi ,³
Yong-Jin Kim ,⁴ Byung-Su Yoo ,⁵ Kyung-Kuk Hwang ,⁶ Hui kyung Jeon ,⁷
Mi-Seung Shin ,⁸ and Kyu-Hyung Ryu ¹

¹Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea

²Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

³Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

⁴Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

⁵Division of Cardiology, Department of Internal Medicine, Yonsei University Wonju Severance Christian Hospital, Wonju, Korea

⁶Division of Cardiology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea

⁷Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Korea

⁸Division of Cardiology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

OPEN ACCESS

Received: Dec 10, 2017

Accepted: Apr 13, 2018

Address for Correspondence:

Kyu-Hyung Ryu, MD, PhD

Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong 18450, Republic of Korea.
E-mail: khryu@hallym.or.kr

© 2018 The Korean Academy of Medical Sciences.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ORCID iDs

Suk-Won Choi
<https://orcid.org/0000-0002-4385-8555>

Seongwoo Han
<https://orcid.org/0000-0002-0327-5021>

Wan Joo Shim
<https://orcid.org/0000-0002-2467-3336>

Dong-Ju Choi
<https://orcid.org/0000-0003-0146-2189>

Yong-Jin Kim
<https://orcid.org/0000-0002-1366-432X>

Byung-Su Yoo
<https://orcid.org/0000-0002-3395-4279>

Kyung-Kuk Hwang
<https://orcid.org/0000-0003-3464-3023>

ABSTRACT

Background: We aimed to evaluate effect of heart rate (HR) reduction on left ventricular reverse remodeling (LVRR) in Korean patients with heart failure with reduced ejection fraction (HFrEF).

Methods: Ambulatory patients with HFrEF, who had paired echocardiograms, N-terminal prohormone brain natriuretic peptide (NT-proBNP), and global assessment score (GAS) at baseline and 6-month (n = 157), were followed up on preset treatment schedule with bisoprolol.

Results: The LVRR occurred in 49 patients (32%) at 6-month. In multivariable analysis, independent predictors associated with LVRR were use of anti-aldosterone agent (odds ratio [OR], 4.18; 95% confidence interval [CI], 1.80–9.71), young age (OR, 0.96; 95% CI, 0.92–0.99), high baseline HR (OR, 3.76; 95% CI, 1.40–10.10), and favorable baseline GAS (OR, 1.73; 95% CI, 1.06–2.81). Beneficial effect of bisoprolol, in terms of LVRR, NT-proBNP, and GAS, was remarkable in the high HR group (baseline HR \geq 75 beats per minute [bpm]), which showed a large HR reduction.


Conclusion: High baseline HR (\geq 75 bpm) showed an association with LVRR and improvement of NT-proBNP and GAS in patients with HFrEF. This seems to be due to a large HR reduction after treatments with bisoprolol.

Trial Registration: ClinicalTrials.gov Identifier: NCT00749034


Keywords: Heart Failure; Left Ventricular Reverse Remodeling; Beta Blocker; Heart Rate

Hui kyung Jeon 

<https://orcid.org/0000-0001-8436-7085>

Mi-Seung Shin 

<https://orcid.org/0000-0002-0273-0109>

Kyu-Hyung Ryu 

<https://orcid.org/0000-0001-9329-2716>

Trial Registration

ClinicalTrials.gov Identifier: [NCT00749034](https://clinicaltrials.gov/ct2/show/study/NCT00749034)

Disclosure

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Ryu KH, Han SW. Data curation: Choi SW, Han SW. Formal analysis: Choi SW, Han SW. Funding acquisition: Ryu KH. Investigation: Shim WJ, Choi DJ, Kim YJ, Yoo BS, Hwang KK, Jeon HK, Shin MS. Writing - original draft: Choi SW. Writing - review & editing: Ryu KH.

INTRODUCTION

High heart rate (HR) is known to be associated with increased cardiovascular events and mortality in populations of various diseases, such as hypertension,¹ coronary artery disease,² and heart failure (HF).^{3,4} In particular, since the publication of the results of the systolic heart failure treatment with the I_f inhibitor ivabradine trial (SHIFT),⁵ resting HR as a modifying risk factor of HF has been highlighted. As a main HR-lowering agent, a beta blocker is the mandatory medication in the management of heart failure with reduced ejection fraction (HFrEF) along with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Although various aspects of pleiotropic benefits of a beta blocker had been suggested,⁶ a recent meta-analysis showed that the benefit of beta blockers in the management of HFrEF is mainly related to the reduction of HR.⁷ In addition, the magnitude of HR reduction in patients with HFrEF receiving beta blockers showed close correlation with improvement of all-cause mortality and left ventricular ejection fraction (LVEF).⁸

Although lowering the HR is considered to be very important, baseline high HR — which has a large portion of HR reduction — consistently showed an association with increased mortality in large randomized controlled studies, even after treatment with maximal tolerable doses of beta blockers.^{2,3} However, these trials were mainly conducted in western patients who are known to be less sensitive to beta blockers than Asian patients in terms of blood pressure (BP) and HR.^{9,10} Therefore, we hypothesized that Korean patients with HFrEF — who are known to be more sensitive to bisoprolol than western patients — would show more favorable outcomes in terms of left ventricular reverse remodeling (LVRR) when they achieved maximal HR reduction with high baseline HR (≥ 75 beats per minute [bpm]) after treatment with maximal tolerable doses of bisoprolol. Also, we compared the values of N-terminal prohormone brain natriuretic peptide (NT-proBNP) and global assessment score (GAS) according to baseline HR 75 bpm after treatment with bisoprolol.

METHODS

Study design and population

This is a prospective, multi-center, and observational study, conducted in 11 university hospitals in Korea. Ambulatory patients with new-onset HF were eligible for inclusion if they 1) were older than 18 years and younger than 80 years, 2) had symptoms of New York Heart Association functional class II–IV and 3) LVEF $< 40\%$ by modified Simpson's method. We excluded patients with grade II or III atrioventricular block, resting HR < 60 bpm, systolic BP < 100 mmHg, serum creatinine > 2.0 mg/dL, decompensated HF, myocardial infarction or cerebrovascular disease within three months, percutaneous coronary intervention or coronary artery bypass surgery within 6 months, serious valvular heart disease, heart transplantation, chronic obstructive pulmonary disease, contraindications to a beta blocker, and other serious systemic diseases.

Treatment protocol

Study patients received optimal treatment for HF (defined as any combination of diuretics and an ACE inhibitor/ARB) before starting bisoprolol. Cardiac glycosides could also be prescribed. As shown in **Fig. 1**, patients visited each hospital at an interval of two weeks and bisoprolol was up-titrated according to a pre-set schedule of 10 weeks. Bisoprolol was initially prescribed from 1.25 mg/day and increased by 1.25 mg at each visit up to 5 mg/day, and then by 2.5 mg




Fig. 1. Preset schedule of dose titration of bisoprolol. Bisoprolol was initially prescribed from 1.25 mg/day and increased by 1.25 mg at each visit up to 5 mg/day, and then by 2.5 mg until reaching a target dose of 10 mg/day. If there was no contraindication to increasing bisoprolol dose (hypotension, bradycardia, dyspnea, or weakness), bisoprolol was increased to the next dosage. NT-proBNP = N-terminal prohormone brain natriuretic peptide, GAS = global assessment score.

until reaching a target dose of 10 mg/day. Dose titration of bisoprolol was monitored by other coordinating investigators, and if there was no contraindication to increasing bisoprolol dose (hypotension, bradycardia, dyspnea, or weakness), dose of bisoprolol was increased to the next dosage by the other coordinating investigators. During the phase of up-titration or maintenance, bisoprolol dose could be reduced when systolic BP was lower than 80 mmHg or HR less than 50 bpm, or if the patients developed decompensated HF.

Outcome measurements

We performed paired 2D echocardiography and also evaluated NT-proBNP and GAS of HF at baseline and 6 months. We observed whether LVRR occurred at six months or not and compared baseline characteristics of patients with LVRR with those of patients without LVRR. We also compared values of NT-proBNP and GAS at baseline with those at 6 months. LVRR was defined as an increase in LVEF from $\geq 10\%$ to a final value of $> 35\%$, accompanied by a decrease in left ventricular end-diastolic dimension (LVEDD) $\geq 10\%$ as assessed by echocardiography at six months. GAS was evaluated using a prepared questionnaire consisting of six points: markedly improved (5), moderately improved (4), mildly improved (3), no change (2), worsened (1), and unassessable (0).^{11,12} In addition, we analyzed prognostic value of predetermined baseline HR (75 bpm) in terms of LVRR and also compared characteristics of patients with high baseline HR (≥ 75 bpm) with low baseline HR (< 75 bpm).

Statistical analysis

Continuous variables were expressed as mean \pm standard deviation (SD) and compared by using t-test or Wilcoxon's rank-sum test. Categorical data was expressed as frequencies and percentages and compared by using χ^2 test or Fisher's exact test. Continuous variables were compared using student t-test or by the nonparametric Mann-Whitney U test. In univariate analysis, variables that differed significantly between groups with and without LVRR were entered into a stepwise logistic regression analysis for identification of independent predictors of LVRR at baseline. To address the risk of overfitting in a multivariate logistic regression model, univariate logistic regression was performed for all variables included in

the model, and two multivariate models were created using five predictors of LVRR with the best F statistic at baseline or five significant predictors of LVRR in previous stepwise logistic regression analysis. For all tests, a probability value of $P < 0.05$ was considered significant. All statistical analyses were performed using the statistical software SPSS (SPSS Inc., Chicago, IL, USA) version 19.0.

Ethics statement

The study was approved by the local ethics committee or Institutional Review Board of each participating center (KUH1010165). All patients provided written informed consent before enrollment.

RESULTS

From October 2010 to August 2012, 186 patients with HFrEF were identified. However, a total of 157 patients were included in the analysis after several violation cases were excluded (Fig. 2). Baseline characteristics of patients are shown in Table 1. Mean age of study patients was 59 years old and 73% of patients were men. Patients with ischemic etiology of HF were 19% and approximately 90% of patients were taking ACE inhibitor or ARB at baseline. Mean value of LVEF was 28%.

LVRR was identified in 49 patients (32%). Baseline characteristics related to the subsequent LVRR in the univariate analysis were as follows: young age, non-ischemic cause, favorable GAS, use of anti-aldosterone agent, high dose of bisoprolol, high diastolic BP, and high baseline HR (≥ 75 bpm). In multivariate analysis, five clinical variables showed independent predictive values for LVRR: use of anti-aldosterone agent, young age, high diastolic BP, favorable baseline GAS, and high baseline HR (≥ 75 bpm; Table 2). Notably, high dose of bisoprolol (≥ 3.75 mg/day) was eventually eliminated statistically in the multivariate analysis and was not related to LVRR.

When compared according to baseline HR 75 bpm, only baseline systolic BP and the magnitude of HR reduction at 10 weeks and six months differed between high HR (≥ 75




Fig. 2. Flow diagram of study patients. A total of 157 patients were included in the analysis after exclusion of several violation cases were excluded. Finally, 112 patients with high baseline HR (≥ 75 bpm) and 45 patients with low baseline HR (< 75 bpm) were compared in the analysis. HR = heart rate, bpm = beats per minute, AV = atrioventricular.

Table 1. Baseline characteristics of study patients

Variables	Overall patients (n = 157)	LVRN absent (n = 108)	LVRN present (n = 49)
Age, yr	59 ± 12	62 ± 11	55 ± 14 ^b
Sex (male), %	115 (73)	83 (77)	32 (65)
Hypertension, %	59 (38)	39 (36)	20 (41)
Diabetes, %	32 (20)	24 (22)	8 (16)
COPD, %	7 (5)	4 (4)	3 (6)
Ischemic cause, %	30 (19)	27 (25)	3 (6) ^b
NYHA class, %			
II	117 (75)	81 (75)	36 (74)
III	38 (24)	25 (23)	13 (27)
IV	2 (1)	2 (2)	0 (0)
GAS (baseline)	2.7 ± 0.9	2.6 ± 0.9	2.8 ± 1.1
ACE inhibitor, %	64 (41)	44 (41)	20 (41)
ARB, %	77 (49)	51 (47)	26 (53)
Anti-aldosterone, %	75 (48)	39 (36)	36 (74) ^c
Diuretics, %	126 (80)	82 (76)	44 (90)
Cardiac glycosides, %	38 (24)	23 (21)	15 (31)
Bisoprolol dose, mg/day	5.4 ± 3.2	5.0 ± 3.1	6.2 ± 3.1 ^a
Bisoprolol dose ≥ 3.75 mg	104 (66)	66 (61)	38 (78) ^a
BMI, kg/m ²	25 ± 4	24 ± 3	25 ± 4.5
Systolic BP, mmHg	123 ± 16	122 ± 16	126 ± 16
Diastolic BP, mmHg	77 ± 13	76 ± 12	81 ± 14 ^a
Heart rate, bpm	83 ± 13	82 ± 14	86 ± 12
Heart rate ≥ 75 bpm, %	112 (71)	70 (65)	42 (86) ^b
Atrial fibrillation, %	34 (22)	25 (23)	9 (18)
Echocardiography			
LVEDD, mm	64 ± 8	63 ± 8	64 ± 8
LVESD, mm	54 ± 12	53 ± 12	56 ± 10
LVEF, %	28 ± 7	29 ± 7	26 ± 7 ^a
LA, mm	46 ± 11	46 ± 8	46 ± 11
Laboratory examination			
Log NT-proBNP, pg/mL	2.9 ± 0.5	2.9 ± 0.6	2.9 ± 0.4
Hemoglobin, g/dL	14 ± 2	14 ± 2	14 ± 2
Sodium, mmol/L	140 ± 2	140 ± 2	140 ± 3
BUN, mg/dL	18 ± 6	18 ± 5	18 ± 7
Creatinine, mg/dL	0.9 ± 0.3	1.0 ± 0.3	1.0 ± 0.3

Values are expressed as mean ± SD or number (%). Data of patients with LVRN were compared with the remaining individuals at baseline. LVRN = left ventricular reverse remodeling, COPD = chronic obstructive pulmonary disease, NYHA = New York Heart Association, GAS = global assessment score, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, BMI = body mass index, BP = blood pressure, bpm = beats per minute, LVEDD = left ventricular end-diastolic dimension, LVESD = left ventricular end-systolic dimension, LVEF = left ventricular ejection fraction, LA = left atrium, NT-proBNP = N-terminal prohormone brain natriuretic peptide, BUN = blood urea nitrogen, SD = standard deviation. P values for comparison between patients with and without LVRN are ^aP < 0.05; ^bP < 0.01; and ^cP < 0.001.

Table 2. Independent predictors for LVRN

Variables	OR (95% CI)	P value
Use of anti-aldosterone agent	6.97 (2.76–17.62)	< 0.001
Old age	0.96 (0.93–0.99)	0.037
High baseline diastolic BP	1.05 (1.01–1.09)	0.013
HR ≥ 75 bpm	3.90 (1.40–10.96)	0.01
High baseline GAS	1.69 (1.04–2.74)	0.035

Multivariate logistic regression of five predictors with statistical significance in stepwise logistic regression. Variables included in stepwise logistic regression: age, ischemic etiology, baseline GAS, anti-aldosterone agent, bisoprolol dose, diastolic BP, and HR ≥ 75 bpm. LVRN = left ventricular reverse remodeling, OR = odds ratio, CI = confidence interval, BP = blood pressure, HR = heart rate, GAS = global assessment score.

bpm) group and low HR (< 75 bpm) group. Notably, resting HR achieved after 6-month bisoprolol treatment did not differ statistically between the two groups (67 vs. 71 bpm). Favorable effect of high HR in terms of LVRN seemed to be due to great magnitude of HR reduction in patients with high HR (≥ 75 bpm) after treatment with bisoprolol (Δ HR after 6

Table 3. Characteristics of the study patients according to baseline HR

Variables	Low HR (< 75 bpm) (n = 45)	High HR (≥ 75 bpm) (n = 112)
Age, yr	61 ± 11	59 ± 13
Sex (male), %	30 (67)	85 (76)
Hypertension, %	16 (36)	43 (38)
Diabetes, %	6 (13)	26 (23)
COPD, %	2 (4)	5 (5)
Ischemic etiology, %	5 (11)	25 (22)
NYHA class, %		
II	31 (69)	86 (77)
III	13 (29)	25 (22)
IV	1 (2)	1 (1)
ACE inhibitor, %	18 (40)	46 (41)
ARB, %	25 (56)	52 (46)
Anti-aldosterone agent, %	21 (47)	54 (48)
Diuretics, %	37 (82)	89 (80)
Cardiac glycosides, %	14 (31)	24 (21)
Bisoprolol dose, mg/day	4.8 ± 3.1	5.6 ± 3.2
Bisoprolol dose ≥ 3.75 mg	25 (56)	79 (71)
BMI, kg/m ²	24 ± 3	25 ± 4
Systolic BP, mmHg	120 ± 15	125 ± 17 ^c
Diastolic BP, mmHg	77 ± 13	77 ± 13
Atrial fibrillation, %	19 (42)	15 (13)
Laboratory examination		
Hemoglobin, g/dL	14 ± 2	14 ± 2
Sodium, mmol/L	140 ± 2	140 ± 3
BUN, mg/dL	17 ± 5	18 ± 6
Creatinine, mg/dL	1.0 ± 0.2	1.0 ± 0.3
Changes of HR		
Baseline, bpm	68	89 ^c
10 wk, bpm	64	73 ^c
6 mon, bpm	67	71
Δ HR (Baseline to 10 wk)	4	16 ^c
Δ HR (Baseline to 6 mon)	1	18 ^c

Values are expressed as mean ± SD or number (%). Data of patients with high baseline HR (≥ 75 bpm) were compared with the remaining individuals at baseline. HR = heart rate, COPD = chronic obstructive pulmonary disease, NYHA = New York Heart Association, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, BMI = body mass index, BP = blood pressure, BUN = blood urea nitrogen, bpm = beats per minute, SD = standard deviation. *P* values for comparison between patients with high (≥ 75 bpm) and low (< 75 bpm) heart rate are ^a*P* < 0.05; ^b*P* < 0.01; and ^c*P* < 0.001.

months: 1 vs. 18 bpm, *P* < 0.001; **Table 3**). LVRR occurred significantly more in the high HR group compared with low HR group. (37.5 vs. 15.6%, *P* = 0.008) after bisoprolol treatment. Although both low and high HR groups showed improved echocardiographic parameters — such as LVEDD, left ventricular end-systolic dimension, and LVEF — after bisoprolol treatment, more favorable morphologic improvement, including LVRR, was observed in high HR group which showed greater magnitude of HR reduction (**Table 4**, **Fig. 3**).

In terms of NT-proBNP and GAS, beneficial effects of bisoprolol were also indicated only in patients with high baseline HR (≥ 75 bpm; **Table 4**, **Fig. 4**). In patients with low baseline HR (< 75 bpm), the extent of improvement in terms of NT-proBNP and GAS was not statistically significant.

DISCUSSION

In the management of patients with HFrEF, HR reduction and target dose of beta blocker have been one of the main concerns. Although most of HF guidelines recommend titration of beta blocker dose up to target dosages based on the pivotal clinical trials of beta

Table 4. Changes of echocardiographic parameters, log NT-proBNP, and GAS after 6-month treatment of bisoprolol

Echocardiography	Baseline	6 mon	Change	P value	
				Baseline vs. 6 mon	Low HR vs. high HR
LVEDD, mm					0.035
Low HR	64 ± 6	61 ± 8	3 ± 5	0.001	
High HR	64 ± 8	58 ± 10	6 ± 8	< 0.001	
LVESD, mm					0.207
Low HR	51 ± 13	45 ± 15	7 ± 15	0.003	
High HR	54 ± 11	45 ± 12	9 ± 13	< 0.001	
LVEF, %					0.023
Low HR	28 ± 7	38 ± 12	10 ± 10	< 0.001	
High HR	28 ± 7	42 ± 12	14 ± 12	< 0.001	
LVR, No. (%)					0.008
Low HR		7 (15.6)			
High HR		42 (37.5)			
Log NT-proBNP, pg/mL					0.122
Low HR	2.9 ± 0.5	2.7 ± 0.6	0.2 ± 0.5	0.051	
High HR	2.9 ± 0.6	2.6 ± 0.6	0.3 ± 0.5	< 0.001	

NT-proBNP = N-terminal pro b-type natriuretic peptide, GAS = global assessment score, HR = heart rate, LVEDD = left ventricular end-diastolic dimension, LVESD = left ventricular end-systolic dimension, LVEF = left ventricular ejection fraction, LVR = left ventricular reverse remodeling.




Fig. 3. Changes of echocardiographic parameters after 6-month treatment of bisoprolol. Although both low and high HR groups showed improved echocardiographic parameters, more favorable morphologic improvement was observed in high HR group. Vertical bars mean standard error of the mean. HR = heart rate, LVEDD = left ventricular end-diastolic dimension, LVESD = left ventricular end-systolic dimension, LVEF = left ventricular ejection fraction.

blockers,^{13,14} some reports have suggested that the main benefits of beta blockers might result from HR reduction, not dose of beta blocker.^{7,15} Meanwhile, although patients with a high baseline HR have a larger portion of achievable HR reduction than patients with low baseline HR, they have been consistently associated with increased adverse cardiovascular outcomes even in clinical trials in which a maximal tolerable dose of beta blockers was




Fig. 4. Improvement of NT-proBNP and GAS after treatment with bisoprolol according to baseline HR 75 bpm. Improvements of log NT-proBNP and GAS were only indicated in patients with high baseline HR. NT-proBNP = N-terminal prohormone brain natriuretic peptide, GAS = global assessment score, HR = heart rate, bpm = beats per minute.

used.^{2-4,16} This finding might result from insufficient HR reduction in spite of target dose of beta blocker and also insensitivity to beta blockers in some western patients with HFrEF. Additional HR reduction in HFrEF patients with treatment of beta blockers has already been shown to be beneficial in terms of mortality in the clinical trial, evaluating a heart-rate modifying agent, ivabradine.⁵ In addition, most of landmark clinical trials regarding beta blockers rarely included any Asian patients with HF, who might have different genetic inheritances to beta blockers.^{17,18}

Asian people are known to be more sensitive to beta blockers in terms of HR and BP than western people.⁹ In the SHIFT study, Asian patients showed an association with not being on a beta blocker or being on a low dose of beta blocker.¹⁰ Besides, in real world practice, frequency of beta blocker use in Korean patients with HF was consistently lower (44%) than that of western patients.^{10,19-21} These reports highlight the difficulty of beta blocker use and high sensitivity to beta blockers in Korean HF patients. On the basis of this evidence, high baseline HR in Korean patients with HFrEF seems to have different clinical significance in the management of HFrEF. In the current study, high baseline HR, not achieved HR at 10 weeks or 6 months, showed independent association with LVRR after maximal tolerable dose of bisoprolol treatment. This is clearly contrasted with previous reports, which consistently showed an association of high baseline HR with adverse cardiovascular outcomes in HF patients.²⁻⁴ However, in the SHIFT trial, patients with baseline HR higher than the median received greater event-reducing benefit from ivabradine than those with HR lower than the median.⁵ Therefore, we could assume that more cardiovascular events in western patients with high baseline HR might be due to insufficient reduction of HR. We could also presume that Korean patients with HFrEF and high baseline HR, who are more sensitive to bisoprolol, had a more beneficial effect in terms of LVRR after bisoprolol treatment because they mostly achieved maximal magnitude of HR reduction.

The advantages of high HR reduction in Korean HF patients, on condition of maximal tolerable dose of bisoprolol, encompassed not only LVRR but also NT-proBNP and GAS. NT-proBNP values improve with treatment of chronic HF,^{22,23} with lowering levels of time correlating with improved clinical outcomes.^{24,25} In addition to LVRR, which represents morphologic changes, NT-proBNP and GAS showed significant improvement in patients with high baseline HR (≥ 75 bpm) and high HR reduction. This finding also supports the favorable

effects of high baseline HR (≥ 75 bpm) and HR reduction in Korean HF patients, in that greater morphologic, functional, and symptomatic improvements were achieved.

Lastly, although the low HR group, which showed only 1 bpm HR-lowering with bisoprolol treatment, had a trend to take low dose bisoprolol compared to the high HR group, they were very insensitive to bisoprolol in terms of HR. This finding tells us that there is heterogeneous response to bisoprolol in Korean HF patients who might have different levels of sympathetic nervous activity.

This study has several limitations. First, this study used surrogate markers of HF, such as LVRR and NT-proBNP. Therefore, direct comparison of the current study with large clinical trials, in which the primary endpoint was cardiovascular mortality, might be inappropriate. However, improvement of surrogate markers of HF such as LVEF or NT-proBNP showed consistent benefit of cardiovascular mortality and morbidity in previous clinical trials.^{12,26,27} Second, reliability of regression analysis is driven by the number of events, multivariate models including more than five independent variables for prediction of 49 events might be inaccurate. Also, other clinical variables that were not included in the analysis could influence the result. Finally, the ischemic origin of HF patients was slightly lower (19%) compared with other cohorts of HFrEF.^{3,4} Due to different characteristics of current study patients, it could be inappropriate to generalize the results of the current study to other HF patients.

In conclusion, high baseline HR (≥ 75 bpm) showed an association with LVRR and improvement of NT-proBNP and GAS in patients with HFrEF after treatment with bisoprolol. This seems to be due to a large HR reduction in Korean HF patients. This finding supports the current concept of importance of HR reduction in management of patients with HFrEF.

REFERENCES

1. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International Verapamil-SR/trandolapril Study (INVEST). *Eur Heart J* 2008;29(10):1327-34.
[PUBMED](#) | [CROSSREF](#)
2. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. *Lancet* 2008;372(9641):817-21.
[PUBMED](#) | [CROSSREF](#)
3. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. *Circulation* 2001;103(10):1428-33.
[PUBMED](#) | [CROSSREF](#)
4. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. *Lancet* 2010;376(9744):886-94.
[PUBMED](#) | [CROSSREF](#)
5. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010;376(9744):875-85.
[PUBMED](#) | [CROSSREF](#)
6. Krum H. Sympathetic activation and the role of beta-blockers in chronic heart failure. *Aust N Z J Med* 1999;29(3):418-27.
[PUBMED](#) | [CROSSREF](#)
7. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. *Ann Intern Med* 2009;150(11):784-94.
[PUBMED](#) | [CROSSREF](#)

8. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. *Am J Cardiol* 2008;101(6):865-9.
[PUBMED](#) | [CROSSREF](#)
9. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. *N Engl J Med* 1989;320(9):565-70.
[PUBMED](#) | [CROSSREF](#)
10. Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I_f inhibitor ivabradine Trial) study. *J Am Coll Cardiol* 2012;59(22):1938-45.
[PUBMED](#) | [CROSSREF](#)
11. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. *Circulation* 1996;94(11):2800-6.
[PUBMED](#) | [CROSSREF](#)
12. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. *Circulation* 1996;94(11):2793-9.
[PUBMED](#) | [CROSSREF](#)
13. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013;62(16):e147-239.
[PUBMED](#) | [CROSSREF](#)
14. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2012;33(14):1787-847.
[PUBMED](#) | [CROSSREF](#)
15. Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). *J Am Coll Cardiol* 2002;40(3):491-8.
[PUBMED](#) | [CROSSREF](#)
16. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. *Eur Heart J* 2005;26(10):967-74.
[PUBMED](#) | [CROSSREF](#)
17. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353(9146):9-13.
[PUBMED](#) | [CROSSREF](#)
18. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med* 1996;334(21):1349-55.
[PUBMED](#) | [CROSSREF](#)
19. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J* 2005;149(2):209-16.
[PUBMED](#) | [CROSSREF](#)
20. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. *Eur Heart J* 2003;24(5):464-74.
[PUBMED](#) | [CROSSREF](#)
21. Lee SE, Cho HJ, Lee HY, Yang HM, Choi JO, Jeon ES, et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. *Eur J Heart Fail* 2014;16(6):700-8.
[PUBMED](#) | [CROSSREF](#)
22. Frantz RP, Olson LJ, Grill D, Moualla SK, Nelson SM, Nobrega TP, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. *Am Heart J* 2005;149(3):541-7.
[PUBMED](#) | [CROSSREF](#)

23. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation* 2003;107(9):1278-83.
[PUBMED](#) | [CROSSREF](#)
24. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. PredischARGE B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. *J Am Coll Cardiol* 2004;43(4):635-41.
[PUBMED](#) | [CROSSREF](#)
25. Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Soucek J, et al. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. *J Card Fail* 2009;15(4):293-9.
[PUBMED](#) | [CROSSREF](#)
26. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol* 1994;24(5):1310-20.
[PUBMED](#) | [CROSSREF](#)
27. Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. *Lancet* 2003;362(9377):14-21.
[PUBMED](#) | [CROSSREF](#)